Key Takeaways:

• The German pharmaceutical packaging giant sold Centor US Holding and its global Primary Packaging Plastics business.
• The combined enterprise value of the deal is approximately 1.5 billion euros ($1.7 billion).
• The deal marks a strategic pivot toward high-value pharmaceutical packaging and drug delivery systems for Apax.

Gerresheimer sold Centor and its global primary packaging plastics business to Apax Funds for $1.7 billion.

WHO: Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech, and cosmetic industries. The Group offers a comprehensive portfolio of primary packaging solutions including closures and accessories, as well as drug delivery systems, medical devices, and solutions for the health industry. The product range includes infusion, dropper, and syrup bottles, tablet containers, vials, syringes, pens, auto-injectors, inhalers, ampoules, cartridges, and on-body devices as well as digital solutions for therapy support. With 39 production sites in Europe, America, and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around €2.3 billion in 2025 and employs over 13,000 people.

Apax, a global private equity advisory firm with more than 50 years of experience, has raised and advised funds with aggregate commitments of approximately $80 billion, focusing on mid-market businesses across technology, services, and internet/consumer sectors.

WHY: Gerresheimer will use the expected cash inflows to significantly optimize its capital and financing structure by considerably decreasing its leverage, as the company focuses...